Denali Therapeutics receives FDA accelerated approval for AVLAYAH
DNLIDYNVYGRATHE
Statements (5)
- Neutral
Voyager Therapeutics Inc. received FDA approval for VY1706, a gene therapy for Alzheimer's that targets extracellular and intracellular tau.
- Neutral
Alterity Therapeutics Limited announced an End-of-Phase 2 meeting with the U.S. Food and Drug Administration regarding its pivotal Phase 3 program for ATH434 in treating Multiple System Atrophy.
- Neutral
Dyne Therapeutics Inc. submitted its official Biologics License Application to the FDA for its new Duchenne disease treatment.
- Bullish
Denali Therapeutics received FDA accelerated approval for AVLAYAH, a treatment for Hunter syndrome (MPS II)
- Bullish
Denali Therapeutics (DNLI) is likely to see a positive market reaction following FDA accelerated approval of AVLAYAH for Hunter syndrome.